Angle parsortix presentation 07oct11


Published on

Major medical diagnostic development for ANGLE.

Patented technology for separating rare cells from blood.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Angle parsortix presentation 07oct11

  1. 1. An Introduction to PARSORTIXPresented by:Andrew Newland, Chief ExecutiveShane Booth, CEO, Parsortix7 October 2011
  2. 2. Major medical diagnostic development for ANGLEParsortixPatented technology forseparating rare cells from bloodForward-Looking StatementsThis presentation and the associated commentary contains certain forward-looking statementsbased on current expectations, forecasts and assumptions that involve significant risks anduncertainties. These statements are based on information currently available to the Company; andANGLE / Parsortixs actual results could differ materially from those stated or implied, due to risksand uncertainties associated with its business.Forward-looking statements include statements regarding expectations, beliefs, intentions orstrategies regarding the future and can be identified by forward-looking words such as “potential”,“target”, “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “should”, “will”,and “would” or similar words. ANGLE assumes no obligation to update the information included inthis presentation, whether as a result of new information, future events or otherwise. © ANGLE plc 2011 Page 2
  3. 3. Market for circulating tumour cell (CTC) separation device Use of CTC cell counting (simple product) for: − Research product (does not need regulatory approval) − Monitoring patient response to chemotherapy − Monitoring patients in remission to identify CTC ahead of secondary tumours 1.2 million new cancer patients per annum in the US market alone* − Each patient may need to be monitored over 30 times Target: potential therapeutic application for a product recovering cells − A pressing need for CTC recovery in relation to lung, pancreatic, and colo-rectal cancers as tumour access for biopsy difficult − These cancers account for approximately one third of the total number of cases annually in the US ANGLE may develop the product initially cancer by cancer *Source : US National Cancer Institute in 2010 © ANGLE plc 2011 Page 3
  4. 4. Parsortix: separation cassette schematic Cassette components Fully assembled cassette Cassette housing © ANGLE plc 2011 Page 4
  5. 5. Captured cells: whole blood control and spiked with SK-Br-3ControlSpiked withbreast cancercells © ANGLE plc 2011 Page 5
  6. 6. Chromogenic staining of SK-Br-3 cellsStained breastCancer cellsVisual IDbreast cancercells Identified cells marked using cytokeratin-18 © ANGLE plc 2011
  7. 7. Development Plan Finalise work on characterising the separation device including flow and volume capability Finalise market requirements for device Optimise design of separation device (next generation) Establish collaboration with cancer research centre(s) Separation of CTCs from cancer patient blood Beta test next generation separation device Final design of separation device Manufacture in quantity Initiate sales for research purposesTarget for completion mid 2012 © ANGLE plc 2011 Page 7
  8. 8. Newsflow potentialQuarter ended 31-Oct-11 31-Jan-12 30-Apr-12 31-Jul-12 31-Oct-12 31-Jan-13 30-Apr-13 31-Jul-13 Continue and expand sales for research purposes Establish Optimise Initiate sales collaborative separation for research Comparative studies to support FDA and CE Mark research with cassette and purposes submission leading Cancer consumable FDA/CE Mark Centres in the US design approval Validation of and UK initial findingsParsortix Advance discussions with (completed) Corporate Partners Consider joint Corporate deal/ Capture CTCs in development distribution cancer patient Establish world programmes partner finalised Target for blood leading Scientific with Corporate clinical product Advisory Board Partners launch and salesAcolyte Completion of Judgement on ANGLE decision on Potential for 3MBiomedica Acolyte case Acolyte case case against 3M settlement Launch of Completion of Potential forGeomerics Battlefield3 and milestone 3 for trade sale Need for Speed major corporate Potential for Potential for Retrospective Prospective studyNovocellus milestone product sales study results results payments and royalties = key value triggers © ANGLE plc 2011 Page 8
  9. 9. Near-term commercial potential Target sales launch of product for research purposes mid 2012 − No requirement for regulatory approval − Immediate market potential − Astra Zeneca 20,000 separations p.a. with one research lab − Early sales potential $25m p.a. Target FDA approval of product for clinical use mid 2013 Clinical market for “simple counting product” estimated at $4bn p.a. in US market alone Gross margin in excess of 75% Significant corporate interest for collaboration with more complex productsThe key is a simple, effective product © ANGLE plc 2011 Page 9
  10. 10. Legal disclaimerThe information and opinions contained in this presentation are provided as at the date hereof and are subject to amendment(without notice), verification and completeness. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on,directly or indirectly, to any other person or published in whole or in part for any purpose. This document is being provided torecipients on the basis that they keep confidential any information contained herein or otherwise made available, whetherorally or in writing, in connection with the Company. Neither this document or any part of this document nor any copy of itmay be sent to or taken into the United States of America, Canada, Australia, Japan, the Republic of South Africa or theRepublic of Ireland, nor may it be distributed to, directly or indirectly, to any US person (within the meaning of regulation Spromulgated under the United States Securities Act of 1933, (as amended) (the “US Securities Act”)). This document does notconstitute an offer to buy or to subscribe for, or the solicitation of an offer to buy or to subscribe for securities in theCompany. To the extent this document is received or used in jurisdictions outside the UK, any such recipient or user shouldinform themselves about and observe any applicable legal requirements. Neither this document nor any part of this documentshould be copied or distributed by recipients and, in particular, should not be distributed by any means, including electronictransmission, to persons with addresses in the United States of America (or any of its territories or possessions) Canada,Australia, Japan, the Republic of South Africa or the Republic of Ireland or to any citizens, residents or nationals thereof, or toany corporation, partnership or other entity created or organised under the laws thereof or in any other country outside theUnited Kingdom where such distribution may lead to a breach of any law or regulatory requirement. Any such distributioncould result in violation of the laws of such countries.This document does not constitute or form any part of any offer or invitation or other solicitation or recommendation topurchase any securities in the Company and does not constitute or form part of a prospectus. No reliance may be placed forany purpose whatsoever on the information, representation or opinions. This document should not be considered as the giving of investment advice by the Company or any of its shareholders,directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its ownindependent assessment of the Company after making such investigations and taking such advice as may be deemednecessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements ofsubjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.Neither the Company nor any other person makes any guarantee, representation or warranty, express or implied, as to theaccuracy, completeness or fairness of the information and opinions contained in this document, nor does the Company acceptany responsibility or liability whatsoever for any loss howsoever arising from any use of this document or its contents orotherwise arising in connection therewith. © ANGLE plc 2011 Page 10